Results 51 to 60 of about 159,720 (266)

A Curvilinear-Path Umbrella Sampling Approach to Characterizing the Interactions Between Rapamycin and Three FKBP12 Variants

Frontiers in Molecular Biosciences, 2022
Rapamycin is an immunosuppressant macrolide that exhibits anti-proliferative properties through inhibiting the mTOR kinase. In fact, the drug first associates with the FKBP12 enzyme before interacting with the FRB domain of its target.
Dhananjay C. Joshi, Charlie Gosse, Shu-Yu Huang, Jung-Hsin Lin, Jung-Hsin Lin, Jung-Hsin Lin, Jung-Hsin Lin, Jung-Hsin Lin   +7 more
doaj   +1 more source

Cancer prevention with rapamycin

Oncotarget, 2023
Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer by directly targeting pre-cancerous cells and, indirectly, by slowing down organism aging. Cancer is an age-related disease and, figuratively, by slowing down time (and aging), rapamycin may delay cancer.
openaire   +2 more sources

Identification and characterisation of calcitonin receptor isoforms expressed in glioblastoma derived glioma stem and U‐87 MG cells

FEBS Open Bio, EarlyView.
Glioblastoma cells express calcitonin receptor variants (CT receptor isoforms) that may help them survive stress. Using qPCR, transcript‐specific long‐read nanopore sequencing, immunofluorescence co‐localisation and comparative sequence analysis, this study identifies a novel alternatively spliced CALCR transcript that encodes the CTb receptor isoform ...
Pragya Gupta, Sebastian GB Furness, Tahereh Gharbi, Ric De Paoli‐Iseppi, Shweta S. Joshi, Michael Clark, David L. Hare, Peter Wookey   +7 more
wiley   +1 more source

Rapamycin Alleviates Heart Failure Caused by Mitochondrial Dysfunction and SERCA Hypoactivity in Syntaxin 12/13 Deficient Models

Advanced Science
SYNTAXIN 12/13 (STX12), a member of the syntaxin protein family enriched in the brain and heart, plays important roles in vesicle recycling. Currently, the role of STX12 in cardiovascular physiology remains unclear.
Run‐Zhou Yang, Fang Li, Jiao Liu, Shu‐Ang Li, Dan‐Hua Liu, Zhuanbin Wu, Pei‐Pei Liu, Wenju Liu, Bin Zhou, Cizhong Jiang, Haibing Zhang, Ying Yu, Jian‐Sheng Kang   +12 more
doaj   +1 more source

Rapamycin-induced phosphaturia [PDF]

Nephrology Dialysis Transplantation, 2010
The mammalian target of rapamycin (mTOR) is known to stimulate a variety of transport mechanisms including the intestinal phosphate transporter NaPi-IIb. The present study was performed to elucidate whether mTOR similarly regulates the major renal tubular phosphate transporter NaPi-IIa.To this end, NaPi-IIa was expressed in Xenopus oocytes with or ...
Daniela S, Kempe, Miribane, Dërmaku-Sopjani, Henning, Fröhlich, Mentor, Sopjani, Anja, Umbach, Goverdhan, Puchchakayala, Anna, Capasso, Florian, Weiss, Michael, Stübs, Michael, Föller, Florian, Lang   +10 more
openaire   +2 more sources

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

β‐Catenin/c‐Myc Axis Modulates Autophagy Response to Different Ammonia Concentrations

Advanced Biology, Volume 9, Issue 3, March 2025.
Ammonia, detoxified by the liver into urea and glutamine, impacts autophagy differently at varying levels. Low ammonia activates autophagy via c‐Myc and β‐catenin, while high levels suppress it. Using Huh7 cells and Spf‐ash mice, c‐Myc's role in cytoprotective autophagy is revealed, offering insights into hyperammonemia and potential therapeutic ...
S. Sergio, B. Spedicato, G. Corallo, A. Inguscio, M. Greco, D. Musarò, D. Vergara, A. F. Muro, G. De Sabbata, L. R. Soria, N. Brunetti Pierri, M. Maffia   +11 more
wiley   +1 more source

Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization

Nanomaterials, 2016
Recently, the use of mammalian target of rapamycin (mTOR) inhibitors, in particular rapamycin (Rp), has been suggested to improve the treatment of neurodegenerative diseases.
Alice Polchi, Alessandro Magini, Jarosław Mazuryk, Brunella Tancini, Jacek Gapiński, Adam Patkowski, Stefano Giovagnoli, Carla Emiliani   +7 more
doaj   +1 more source

Engineered Microvascular Model of the Blood–Brain–Tumor Barrier Reveals Endothelial Remodeling in Diffuse Midline Glioma

Advanced Healthcare Materials, EarlyView.
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett, Yann S. Vanrobaeys, Tessy Teboh, Zakiya Smith, Anderson Scott, Cynthia Hajal, Paula T. Hammond, Joelle P. Straehla   +7 more
wiley   +1 more source

Inhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and Beyond [PDF]

Cold Spring Harbor Perspectives in Medicine, 2016
Rapamycin is a Food and Drug Administration (FDA)-approved immunosuppressant and anticancer agent discovered in the soil of Easter Island in the early 1970s. Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways.
openaire   +2 more sources